References
- SchechterALSternDFVaidyanathanLThe neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigenNature198431259945135166095109
- SlamonDGodolphinWJonesLStudies of the HER-2/neu proto-oncogene in human breast and ovarian cancerScience198924449057077122470152
- RossJSSlodkowskaEASymmansWFPusztaiLRavdinPMHortobagyiGNThe HER-2 receptor and breast cancer: ten years of targeted anti–HER-2 therapy and personalized medicineThe Oncologist200914432036819346299
- HudisCATrastuzumab – mechanism of action and use in clinical practiceN Engl J Med20073571395117611206
- PerezEARomondEHSumanVJUpdated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancerPaper presented at: ASCO Annual Meeting Proceedings Part I2007San Francisco
- SmithIProcterMGelberRD2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trialLancet20073699555293617208639
- SlamonDEiermannWRobertNAdjuvant trastuzumab in HER2-positive breast cancerN Engl J Med2011365141273128321991949
- AgusDBGordonMSTaylorCPhase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancerJ Clin Oncol200523112534254315699478
- ChenXYeungTKWangZEnhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3Biochem Biophys Res Commun2000277375776311062025
- GianniLLladóABianchiGOpen-label, Phase II, multicenter, randomized study of the efficacy and safety of two dose levels of pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2–negative metastatic breast cancerJ Clin Oncol20102871131113720124183
- BaselgaJGelmonKAVermaSPhase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer that progressed during prior trastuzumab therapyJ Clin Oncol20102871138114420124182
- BaselgaJCortésJKimS-BPertuzumab plus trastuzumab plus docetaxel for metastatic breast cancerN Engl J Med2012366210911922149875
- SwainSMKimSBCortesJConfirmatory overall survival (OS) analysis of CLEOPATRA: a randomized, double-blind, placebo-controlled Phase III study with pertuzumab (P), trastuzumab (T), and docetaxel (D) in patients (pts) with HER2-positive first-line (1L) metastatic breast cancer (MBC)Cancer Research20127224 Suppl 3 abstract P5-18-26
- Lewis PhillipsGDLiGDuggerDLTargeting HER2-positive breast cancer with trastuzumab-DM1, an antibody–cytotoxic drug conjugateCancer Research200868229280929019010901
- KropIEBeeramMModiSPhase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancerJ Clin Oncol201028162698270420421541
- KropIELoRussoPMillerKDA Phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabineJ Clin Oncol201230263234324122649126
- VermaSMilesDGianniLTrastuzumab emtansine for HER2-positive advanced breast cancerN Engl J Med2012367191783179123020162
- DiérasVHarbeckNBuddGTTrastuzumab emtansine in HER2-positive metastatic breast cancer: pooled safety analysis from seven studiesCancer Research20127224 Suppl 3P5-18-06
- EllisPBarriosCImYPatreMBranleFPerezEMARIANNE: A phase III, randomized study of trastuzumab-DM1 (T-DM1) with or without pertuzumab (P) compared with trastuzumab (H) plus taxane for first-line treatment of HER2-positive, progressive, or recurrent locally advanced or metastatic breast cancer (MBC)J Clin Oncol201129Suppl abstr TPS102
- AlvarezRHValeroVHortobagyiGNEmerging targeted therapies for breast cancerJ Clin Oncol201028203366337920530283
- BaselgaJAlbanellJRuizAPhase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancerJ Clin Oncol200523235323533315939921
- RobertsonJGutteridgeECheungKOwersRGefitinib (ZD1839) is active in acquired tamoxifen (TAM)-resistant oestrogen receptor (ER)-positive and ER-negative breast cancer: results from a phase II studyProc Am Soc Clin Oncol200322 abstr 23
- AlbainKElledgeRGradisharWJNataleRBOpen-label, phase II, multicenter trial of ZD 1839 (‘Iressa’) in patients with advanced breast cancerBreast Cancer Research And Treatment200276(S33)Suppl 1 abstr 20
- von MinckwitzGJonatWFaschingPA multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancerBreast Cancer Res Treat200589216517215692759
- CiardielloFTroianiTCaputoFPhase II trial of gefitinib combined with docetaxel as first-line therapy in patients with metastatic breast cancerBr J Cancer200694111604160916685276
- EngebraatenOEdvardsenHLøkkevikEGefitinib in combination with weekly docetaxel in patients with metastatic breast cancer caused unexpected toxicity: results from a randomized Phase II clinical trialISRN Oncology201220128
- SmithIEWalshGSkeneAA Phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancerJ Clin Oncol200725253816382217679728
- CarlsonRWO’NeillAVidaurreTGomezHLBadveSRandomized phase II trial of gefitinib plus anastrozole or fulvestrant in postmenopausal, metastatic breast cancerJ Clin Oncol20092715S1013
- TwelvesCTrigoJMJonesRErlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: a dose-escalation studyEur J Cancer200844341942618249110
- DicklerMNRugoHSEberleCAA phase ii trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancerClin Cancer Res200814237878788319047117
- KaurHSilvermanPSinghDCooperBWFuPKrishnamurthiSToxicity and outcome data in a phase II study of weekly docetaxel in combination with erlotinib in recurrent and/or metastatic breast cancer (MBC)J Clin Oncol20062418S10623
- MontagnaECancelloGBagnardiVMetronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activityClin Breast Cancer201212320721422520733
- GrahamDLHillmanDWHobdayTJN0234: Phase II study of erlotinib (OSI-774) plus gemcitabine as first-or second-line therapy for metastatic breast cancer (MBC)J Clin Oncol20052316S64415659512
- HobdayTJStellaPJFitchTRN0436: a phase II trial of irinotecan plus cetuximab in patients with metastatic breast cancer and prior anthracycline and/or taxane-containing therapyJ Clin Oncol200826Suppl abstr 1081
- CareyLARugoHSMarcomPKTBCRC 001: randomized phase ii study of cetuximab in combination with carboplatin in Stage IV triple-negative breast cancerJ Clin Oncol201230212615262322665533
- GeyerCEForsterJLindquistDLapatinib plus Capecitabine for HER2-Positive Advanced Breast CancerNew England Journal of Medicine2006355262733274317192538
- BaselgaJBradburyIEidtmannHLapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trialThe Lancet3799816633640
- GelmonKABoyleFKaufmanBOpen-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+ metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919J Clin Oncol201230Suppl 15 abstract LBA671
- CameronDCaseyMPressMA phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res TreatDec20081123533543
- LinNUDiérasVPaulDMulticenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer. Clinical Cancer ResearchFebruary 15200915414521459
- PivotXSemiglazovVŻurawskiBCEREBEL (EGF111438): An open label randomized phase III study comparing the incidence of CNS metastases in patients (pts) with HER2+ Metastatic Breast Cancer (MBC), treated with Lapatinib plus Capecitabine (LC) versus Trastu-zumab plus Capecitabine (TC)Annals of Oncology201223Suppl 9 Abstract LBA11
- BursteinHJSunYDirixLYNeratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancerJ Clin Oncol20102881301130720142587
- ShawRJCantleyLCRas, PI(3)K and mTOR signalling controls tumour cell growthNature2006441709242443016724053
- JiangBHLiuLZRole of mTOR in anticancer drug resistance: perspectives for improved drug treatmentDrug Resistance Updates: Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy2008113637618440854
- BachelotTBourgierCCropetCRandomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor–positive, human epidermal growth factor receptor 2–negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO StudyJ Clin Oncol201230222718272422565002
- BaselgaJSemiglazovVvan DamPPhase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor–positive breast cancerJ Clin Oncol200927162630263719380449
- BaselgaJCamponeMPiccartMEverolimus in postmenopausal hormone-receptor–positive advanced breast cancerN Engl J Med2012366652052922149876
- Piccart-GebhartMJNoguchiSPritchardKIEverolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trialJ Clin Oncol201230Suppl abstr 559
- WolffACLazarAABondarenkoIRandomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancerJ Clin Oncol201331219520223233719
- BaselgaJTargeting the phosphoinositide-3 (PI3) kinase pathway in breast cancerOncologist201116Suppl 1121921278436
- Stemke-HaleKGonzalez-AnguloAMLluchAAn integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancerCancer Research200868156084609118676830
- TokunagaEKimuraYMashinoKActivation of PI3K/Akt signaling and hormone resistance in breast cancerBreast Cancer200613213714416755107
- EndDWSmetsGToddAVCharacterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitroCancer Research200161113113711196150
- DalencFDoisneau-SixouSFAllalBCTipifarnib plus tamoxifen in tamoxifen-resistant metastatic breast cancer: a negative phase II and screening of potential therapeutic markers by proteomic analysisClin Cancer Res20101641264127120145184
- LiTGuoMGradisharWA phase II trial of capecitabine in combination with the farnesyltransferase inhibitor tipifarnib in patients with anthracycline-treated and taxane-resistant metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1103)Breast Cancer Res Treat2012134134535222547107
- LiTChristosPJSparanoJAPhase II trial of the farnesyltransferase inhibitor tipifarnib plus fulvestrant in hormone receptor-positive metastatic breast cancer: New York Cancer Consortium Trial P6205Ann Oncol200920464264719153124
- JohnstonSSemiglazovVManikhasGA phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapyBreast Cancer Res Treat2008110232733517851757
- GelmonKATischkowitzMMackayHOlaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised studyLancet Oncol201112985286121862407
- TuttARobsonMGarberJEOral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trialLancet376973723524420609467
- O’ShaughnessyJSchwartzbergLSDansoMAA randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC)J Clin Oncol201129Suppl 15 abstr 1007
- RelfMLeJeuneSScottPAEExpression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor β-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesisCancer Res19975759639699041202
- ShihTLindleyCBevacizumab: an angiogenesis inhibitor for the treatment of solid malignanciesClin Ther200628111779180217212999
- MilesDWChanADirixLYPhase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast CancerJ Clin Oncol201028203239324720498403
- MillerKDChapLIHolmesFARandomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast CancerJ Clin Oncol200523479279915681523
- RobertNJDiérasVGlaspyJRIBBON-1: randomized, double-blind, placebo-controlled, phase iii trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2–negative, locally recurrent or metastatic breast cancerJ Clin Oncol201129101252126021383283
- MillerKWangMGralowJPaclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancerN Engl J Med2007357262666267618160686
- BrufskyAHurvitzSAPerezEAFinal overall survival (OS) and safety analyses of RIBBON-2, a randomised phase III trial of bevacizumab (BEV) versus placebo (PL) combined with second line chemotherapy (CT) for HER2-negative-BEV-naive metastatic breast cancer (MBC)J Clin Oncol201230Suppl 27 abstr 100
- CameronDBrownJDentRPrimary results of BEATRICE, a randomized phase III trial evaluating adjuvant bevacizumab-containing therapy in triple-negative breast cancerCancer Research20127224, Suppl 3 Available from: http://cancerres.aacrjournals.org/cgi/content/short/72/24_MeetingAbstracts/S6-5?rss=1Accessed May 20, 2013
- Moreno-AspitiaAMortonRFHillmanDWPhase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336J Clin Oncol2009271111519047293
- BaselgaJSegallaJGMRochéHSorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancerJ Clin Oncol201230131484149122412143
- BarriosCHLiuMCLeeSCPhase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancerBreast Cancer Res Treat2010121112113120339913
- CrownJDierasVStaroslawskaEPhase III trial of sunitinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer (ABC)J Clin Oncol201028Suppl abstr 18
- BerghJBondarenkoIMLichinitserMRFirst-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III studyJ Clin Oncol201230992192922331954
- MillerKDTrigoJMWheelerCA multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancerClin Cancer Res20051193369337615867237
- BoérKLángILlombart-CussacAVandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized phase II studyInvest New Drugs201230268168720830502
- WoodJMBoldGBuchdungerEPTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administrationCancer Res20006082178218910786682
- US National Institutes of HealthPTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer Available from: http://clinicaltrials.gov/ct2/show/results/NCT00216047Accessed June 23rd, 2013